Association between COVID-19 and the incidence of type 1 diabetes in Portugal - a registry study.

Autor: Bjerregaard-Andersen M; Department of Endocrinology and Nephrology, University Hospital of Southern Denmark, Finsensgade 35, 6700, Esbjerg, Denmark. Morten.Bjerregaard-Andersen2@rsyd.dk.; Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark. Morten.Bjerregaard-Andersen2@rsyd.dk.; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark. Morten.Bjerregaard-Andersen2@rsyd.dk., Da Silva J; Institute for Interdisciplinary Research, Doctoral Program in Experimental Biology and Biomedicine (PDBEB), University of Coimbra, Coimbra, Portugal.; CNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-504, Portugal.; CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, 3004-504, Portugal., Diogo R; Hospital Pediátrico de Coimbra, Centro Hospitalar e Universitário de Coimbra (CHUC) E.P.E., Coimbra, Portugal., Claro AR; Departamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHLN) E.P.E., Lisbon, Portugal., Ferro I; Departamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHLN) E.P.E., Lisbon, Portugal., Romana A; Departamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHLN) E.P.E., Lisbon, Portugal., Rocha P; Centro Hospitalar de Leiria E.P.E., Leiria, Portugal., Sá B; Centro Hospitalar de Leiria E.P.E., Leiria, Portugal., Lobarinhas G; Hospital Santa Maria Maior E.P.E., Barcelos, Portugal., Rolim S; Hospital Santa Maria Maior E.P.E., Barcelos, Portugal., Juhl CB; Department of Endocrinology and Nephrology, University Hospital of Southern Denmark, Finsensgade 35, 6700, Esbjerg, Denmark.; Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark., Højlund K; Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark., Fernandes I; Hospital Espírito Santo E.P.E., Evora, Portugal., Antunes S; Hospital Espírito Santo E.P.E., Evora, Portugal., Félix Calha MM; Centro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal., Gama G; Centro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal., Amálio S; Centro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal., Figueiras M; Centro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal., Silva T; Centro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal., Rosado M; Centro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal., Ferrão E; Centro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal., Arez L; Centro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal., Baptista A; Centro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal., Martins Ferreira A; Centro Hospitalar do Tâmega e Sousa E.P.E., Guilhufe, Portugal., Alba D; Centro Hospitalar do Tâmega e Sousa E.P.E., Guilhufe, Portugal., Godinho C; Centro Hospitalar Universitário do Algarve (CHUA) E.P.E., Faro, Portugal., Leite AL; Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG/E) E.P.E., Vila Nova de Gaia, Portugal., Afonso Lopes ML; Unidade de Endocrinologia Pediátrica, Hospital de Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central (CHULC) E.P.E., Lisbon, Portugal., Sampaio ML; Departamento de Pediatria, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHLN) E.P.E., Lisbon, Portugal., Serra-Caetano J; Hospital Pediátrico de Coimbra, Centro Hospitalar e Universitário de Coimbra (CHUC) E.P.E., Coimbra, Portugal., Carvalho E; CNC-UC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-504, Portugal.; CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, 3004-504, Portugal.; Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Casa Costa Alemão, Coimbra, 3030- 789, Portugal.
Jazyk: angličtina
Zdroj: BMC endocrine disorders [BMC Endocr Disord] 2024 Aug 09; Vol. 24 (1), pp. 145. Date of Electronic Publication: 2024 Aug 09.
DOI: 10.1186/s12902-024-01667-5
Abstrakt: Background: Viral respiratory infections may precipitate type 1 diabetes (T1D). A possible association between the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, and the incidence of T1D is being determined. This study was carried out using Portuguese registries, aiming at examining temporal trends between COVID-19 and T1D.
Methods: Hospital data, comparing the incidence before and during the COVID-19 pandemic, from children and young adults diagnosed with new-onset T1D, was acquired beginning in 2017 and until the end of 2022. Data was obtained from nine different Portuguese hospital units. The impact of the COVID-19 pandemic, beginning in March 2020, was assessed comparing the annual numbers of new-onset T1D cases. The annual median levels of glucose, glycated hemoglobin (HbA1c) and fasting C-peptide at T1D diagnosis were compared. The annual number of diabetic ketoacidosis (DKA) episodes among new T1D cases was also assessed at two centers.
Results: In total, data from 574 newly diagnosed T1D patients was analyzed, including 530 (92.3%) children. The mean ages for child and adult patients were 9.1 (SD 4.4) and 32.8 (SD 13.6) years, respectively. 57.8% (331/573) were male, one patient had unknown sex. The overall median (25-75 percentiles) levels of glucose, HbA1c and fasting C-peptide at diagnosis were 454 mg/dL (356-568), 11.8% (10.1-13.4) and 0.50 µg/L (0.30-0.79), respectively. DKA at T1D diagnosis was present in 48.4% (76/157). For eight centers with complete 2018 to 2021 data (all calendar months), no overall significant increase in T1D cases was observed during the COVID-19 pandemic, i.e. 90 cases in 2018, 90 cases in 2019, 112 in 2020 and 100 in 2021 (P for trend = 0.36). Two of the centers, Faro (CHUA) and Dona Estefânia (CHULC) hospitals, did however see an increase in T1D from 2019 to 2020. No significant changes in glucose (P = 0.32), HbA1c (P = 0.68), fasting C-peptide (P = 0.20) or DKA frequency (P = 0.68) at the time of T1D diagnosis were observed over the entire study period.
Conclusion: The T1D incidence did not increase significantly, when comparing the years before and during the COVID-19 pandemic, nor did key metabolic parameters or number of DKA episodes change.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje